Webinars
Available On Demand
Trinity’s Diversity, Equity & Inclusion (DEI) strategy team invites life sciences executives to join a lively discussion on recent research and developments in clinical trial diversity with a focus on racial and ethnic minorities. Herman Sanchez, Chief Business Officer at Trinity Life Sciences, will host this session and moderate a panel with special guests Monique Marsh—Associate Director and Co-Head of Trinity’s Marketing Communications Insights COE, Julie Bayley—Associate Director in Trinity’s Insights practice and Ari King, Associate Consultant.
Key Topics
What…
Watch Now
Blog
Published June 13, 2024
Trinity Life Sciences recently worked with a large global pharma company to develop a new process for creating global value dossiers (GVDs) that better met the needs of regional affiliates. Matt O’Hara, who leads Trinity’s Evidence Strategy practice, shares insights into the project with Mary Fletcher-Louis, who recently joined Trinity to head Trinity’s Value Center of Excellence.
Understanding the Challenge
The project involved reviewing the client’s 15 most recent GVDs and scoring each chapter for effectiveness, ease of use, level…
Read Now
Webinars
Available On Demand
High-impact, optimized marketing communication materials are vital, no matter where a brand is in the product lifecycle. Taking tactical research in general—and concept or message testing in particular—to the next level becomes a key focus. Join Lisa Bailey, a Managing Director in Trinity Life Sciences’ Insights Practice, as she hosts a wide-ranging discussion on tips and tricks from the field with presenters Monique Marsh, Associate Director, Kristen Tierhold, Associate Principal and Sabrina Jordan, Associate Director.
Key Webinar Topics
What approaches…
Watch Now
Blog
Published May 23, 2024
Executive Summary
The global payer landscape is rapidly evolving and is expected to continuously impact manufacturers’ decisions about new launches, portfolio management, trial design and importantly, pricing and market access strategy. In the UK, several policy reforms have been introduced which are expected to improve patient access while balancing financial healthcare sustainability and overall market attractiveness. A few key developments announced or already implemented include:
The shift of the much-debated Voluntary Scheme for Branded Medicines Pricing and Access (VPAS) to…
Read Now
Case Studies
Client Situation
The objective was to develop an advanced machine learning algorithm to predict potential site alerts for HCPs in the target universe
Trinity’s Role
Besides sales rep deployment, the client used these alerts to direct their non-personal promotion like email and digital advertising.
The project was done in 2 phases.
Phase 1:
Data coverage of claims data, EMR data and other sources for incoming site alerts to expand the existing HCP list
Business rule creation to identify incoming site…
Read Now
Blog
Published May 17, 2024
Executive Summary
The Central Social Insurance Medical Council, the key Japanese reimbursement policy panel known as Chuikyo, introduced the 2024 drug pricing reform in April 2024.
Some key features of the reform plan include:
The creation of premiums for incentivizing the early introduction of new innovative therapies in Japan
The establishment of post-listing price adjustment scheme by average foreign price for specific imported drugs at the time of price revision
The simplification of the price maintenance premium (PMP) system so…
Read Now
Webinars
Available On Demand
Join us for the next webinar in our “Making AI Real” webinar series, where we will focus on practical applications of generative AI for Medical Affairs.Medical Affairs teams are rapidly adopting generative AI to work more efficiently and effectively, although key challenges have begun to emerge. In this webinar, we will explore the best use cases that Medical Affairs teams can (and should) be implementing now to make the greatest impact for their organizations—and how to avoid the common pitfalls…
Watch Now
Webinars
Available On Demand
A number of critical manufacturer activities are informed by understanding health technology assessment (HTA) agency behavior across geographies and therapeutic areas—from pipeline, business development and licensing to launch planning preparation through to lifecycle management strategy. Join Max Hunt, a Partner in Trinity Life Sciences’ Evidence, Value, Access & Pricing Practice, as he hosts a lively discussion on the benefits of rapid access to cumulative, compounded learnings generated from in-depth analysis of global HTA recommendations, with presenters Mary Fletcher-Louis, Managing Director…
Watch Now
White Papers
To date, life sciences’ efforts towards driving equitable healthcare have centered around access to care, early identification and prevention. Meanwhile, less attention has been given to the impact of the racial and ethnic homogeneity in trial populations. Clinical trial diversity continues to be one of the greatest challenges pharmaceutical and biotech companies face in ensuring the delivery of medicines that are effective for all people. Diverse clinical trial populations are an integral step in achieving equitable healthcare treatment.
While we…
Read Now
Blog
Published April 30, 2024
Reliable forecast models are a cornerstone of any successful commercialization plan.
The inputs that drive those forecast models are critical.
From 2020 through 2022:
Only
1
in
10
products had performance aligned with forecasted expectations*
Nearly
60% underperformed their forecast expectations
More than
30% overperformed
Forecast models often rely on healthcare professional (HCP)-reported behavioral data.
Various subjective calibration factors are required to render the data usable, even after implementing robust market research design elements.
Data from primary market research (PMR)…
Read Now
